Comparative Pharmacology
Head-to-head clinical analysis: AQUAMEPHYTON versus SYNKAYVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAMEPHYTON versus SYNKAYVITE.
AQUAMEPHYTON vs SYNKAYVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phytonadione (vitamin K1) is a cofactor for hepatic synthesis of clotting factors II, VII, IX, and X. It promotes the carboxylation of glutamate residues on these factors, enabling calcium binding and coagulation activity.
Menadiol sodium diphosphate is a water-soluble form of vitamin K (menadione) that serves as a cofactor for the gamma-carboxylation of glutamic acid residues in clotting factors II, VII, IX, X, and proteins C and S in the liver, enabling their calcium-dependent binding to phospholipid membranes and activation of the coagulation cascade.
Phytonadione (vitamin K1) 10 mg IV or IM, once; for non-urgent reversal of anticoagulation, 2.5-5 mg oral, once.
5 to 15 mg subcutaneously or intramuscularly once daily for 3 to 5 days; for anticoagulant reversal, 1 to 10 mg intravenously at 10 mg/min rate.
None Documented
None Documented
Terminal half-life: ~1.5-2.5 hours (adults); clinical context: short half-life requires repeated dosing for vitamin K deficiency correction; prolonged in liver disease (up to 5-7 hours).
Terminal elimination half-life is approximately 2.5 hours (range 2-4 hours) in healthy adults; prolonged in patients with hepatic dysfunction.
Renal: minimal (<10% as unchanged drug); biliary/fecal: ~50% as metabolites; enterohepatic circulation occurs.
Primarily fecal via bile (approximately 60-70% as metabolites, with little unchanged drug); renal excretion accounts for <5%.
Category C
Category C
Vitamin K
Vitamin K